Status | Study |
Recruiting |
Study Name: FIBrinogen REplenishment in Surgery Condition: Deficiency; Fibrinogen, Acquired Date: 2017-01-27 Interventions: Drug: Octafibrin Octafibrin wi |
Not yet recruiting |
Study Name: Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using myPKFiT® Condition: Hemophilia A Hemophilia Factor VIII Deficiency Date: 2016-12-22 Interventions: Drug: Octocog Alfa Other Names: Advate® Human Factor VIII |
Recruiting |
Study Name: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A Condition: Hemophilia A Date: 2016-12-21 Interventions: Drug: Emicizumab Emicizumab will be administered according to dose and schedule described in respective |
Not yet recruiting |
Study Name: Individualizing Hemophilia Bypassing Agent Therapy Utilizing Thromboelastography Condition: Hemophilia A With Inhibitors Date: 2016-12-19 Interventions: Other: Thromboelastography-Guided Treatment Regimen The thromboelastograph (TEG) will be used to determi |
Recruiting |
Study Name: A Gene Transfer Study for Hemophilia A Condition: Hemophilia A Date: 2016-12-16 Interventions: Genetic: SPK-8011 A novel, bio-engineered, recombinant adeno-associated viral vector carrying human fact |
Active, not recruiting |
Study Name: Post-Marketing Surveillance To Observe Safety And Efficacy Of Xyntha Solofuse Prefilled Syringe Condition: Factor VIII Deficiency, Congenital Factor 8 Deficiency, Congenital Date: 2016-11-30 |
Recruiting |
Study Name: Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products Condition: Hemophilia A Date: 2016-11-24 Interventions: Drug: efmoroctocog alfa extend |
Recruiting |
Study Name: A Clinical Phenotype Based Individualized Prophylaxis in Chinese Hemophilia A Children Condition: Haemophilia Date: 2016-09-01 Interventions: Other: Observe the patient's condition and then change the regimen The patients will be assessed every 3 |
Withdrawn |
Study Name: Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B Condition: Hemophilia B Date: 2013-11-14 Interventions: Biological: IB1001 Prophylaxis (during Treatment and Conti |
Terminated |
Study Name: Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery Condition: Thrombophilia Due to Acquired Antithrombin III Deficiency Date: 2012-02-07 Interventions: Drug: Recombinant antithrombin (rhAT) Subjects will receive an intravenous bolus of 500 units of recombi |